We provide accurate and reproducible tumor measurements to assess response to novel therapies for patients enrolled in oncologic clinical trials.

Our process begins with a thorough review of each trial protocol to ensure that imaging assessment requirements are accurately interpreted and executed as intended. Our highly skilled and experienced team reviews each imaging study using our trial-specific conformance checks to ensure protocol compliance. Results are provided to the clinical team before the patient's office visit which greatly facilitates trial decision-making and patient care.

We work with you to ensure the success of your clinical trial from study initiation to closure

Protocol guidance

We coordinate with study teams and sponsors to ensure that there are no ambiguities in the imaging-related sections of the trial's protocol that would lead to errors in imaging assessment, or inconsistencies across reviewers or participating sites.

Image Review

Radiologists from Dana-Farber Cancer Institute, Massachusetts General Hospital, and Brigham and Women's Hospital provide cancer imaging expertise, enabling high quality and consistent tumor imaging assessments covering over 30 trial-specific tumor response criteria across a variety of cancers and therapeutic areas.

Real-time results reporting

We can provide same-day results in as little as four hours after receipt of patients' imaging exams. We understand that there are times when rapid turnaround of results are needed to support patient care.

Data management

Our clinical trial imaging management system tracks all response-related imaging data generated during the course of a clinical trial, has full audit trails, and is configurable to meet trial-specific requirements and modifications.

Quality assurance and control

We provide confidence in our imaging results through stringent processes implemented throughout the analysis workflow which include, but are not limited to, comprehensive response criteria training and testing, inter- and intra-rater reliability, with random sampling of assessments across imaging analysts, reviewers and response criteria to ensure accuracy, consistency, reproducibility and compliance with trial-specific requirements.

Our cancer center

TIMC has served as the imaging core laboratory for the Dana-Farber/Harvard Cancer Center (DF/HCC) since 2005. Our team of cancer imaging experts ensures reliable, real-time results for over 1,800 active clinical trials. We work hand-in-hand with the DF/HCC to ensure that our team stays well-informed of novel therapies, changes in clinical trial design, execution, and data reporting.

DF/HCC unites the cancer research efforts of five Harvard academic medical centers, including Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital to solve today's most challenging problems in cancer research and care. The DF/HCC Core Facilities are central laboratories that provide critical services to DF/HCC members to promote cross-institutional collaboration. Since its inception, TIMC has processed a variety of imaging exams for over 150,000 visits for patients enrolled in clinical trials.

DF/HCC Core Facilities

Our cancer network

We promote quality, integrity, accuracy, reproducibility, timeliness, and efficiency of clinical trial imaging assessments by aligning cancer centers and imaging teams. We can enhance your imaging review process whether you outsource this responsibility to TIMC or use our innovative informatics platform (formerly known as Precision Imaging Metrics (PIM), exclusively licensed in 2022 from MGH through Yunu, Inc., to manage your own tumor metrics service. Join our growing network of 16 institutions including 10 NCI-designated cancer centers to discover the benefits.

The National Comprehensive Cancer Network (NCCN) recognizes both the TIMC and our clinical trials imaging informatics platform, licensed through Yunu, Inc., as shared resources, which are available to all member institutions to reduce redundancies and improve the ability to conduct research across these institutions. TIMC provides real-time imaging assessment to nine institutions, and the Yunu software is in use at sixteen sites including ten NCI-designated cancer centers nationwide. Our services and software platform have clearly demonstrated an impact in improving clinical trials imaging assessment results turnaround time and compliance with the study protocol as well as streamlining audits. Cancer centers that prefer to manage their own tumor metrics service can use the Yunu system to improve the efficiency, integrity, and quality of their clinical trial imaging reads.

NCCN Shared Resources

Our supporting technologies

TIMC developed innovative informatics solutions to help address your tumor response assessment needs. The Yunu platform is a web-based system that promotes communication, transparency, efficiency, and standardization. Whether you are a sponsor, radiologist, clinical trial team member, or clinician, our imaging and workflow management tools help ensure your clinical trial success.

Yunu, Inc. is a comprehensive cloud-hosted informatics platform that manages the clinical trial imaging needs of cancer centers. Yunu streamlines workflows, imaging review, and reporting, and eliminates inefficient, error-prone tools and practices. It provides clinical research teams the guidance they need to ensure that each patient's cancer imaging exam is measured and monitored in a systematic, unbiased way consistent with trial-specific criteria. Sixteen institutions including ten NCI-designated cancer centers across the country currently use the Yunu platform to assess over 25,000 clinical trial time points per year.

Visit Yunu